111 related articles for article (PubMed ID: 30987652)
1. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
Jin H; Jang Y; Cheng N; Li Q; Cui PF; Zhou ZW; Jiang HL; Cho MH; Westover KD; Tan QY; Xu CX
J Exp Clin Cancer Res; 2019 Apr; 38(1):165. PubMed ID: 30987652
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in
Fanini F; Bandini E; Plousiou M; Carloni S; Wise P; Neviani P; Murtadha M; Foca F; Fabbri F; Vannini I; Fabbri M
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948154
[TBL] [Abstract][Full Text] [Related]
3. miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer.
Palma F; Affinito A; Nuzzo S; Roscigno G; Scognamiglio I; Ingenito F; Martinez L; Franzese M; Zanfardino M; Soricelli A; Fiorelli A; Condorelli G; Quintavalle C
Cancer Gene Ther; 2021 May; 28(5):413-426. PubMed ID: 32948832
[TBL] [Abstract][Full Text] [Related]
4. Sirt1 protects from K-Ras-driven lung carcinogenesis.
Costa-Machado LF; Martín-Hernández R; Sanchez-Luengo MÁ; Hess K; Vales-Villamarin C; Barradas M; Lynch C; de la Nava D; Diaz-Ruiz A; de Cabo R; Cañamero M; Martinez L; Sanchez-Carbayo M; Herranz D; Serrano M; Fernandez-Marcos PJ
EMBO Rep; 2018 Sep; 19(9):. PubMed ID: 30021836
[TBL] [Abstract][Full Text] [Related]
5. PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways.
Naidu S; Shi L; Magee P; Middleton JD; Laganá A; Sahoo S; Leong HS; Galvin M; Frese K; Dive C; Guzzardo V; Fassan M; Garofalo M
Sci Rep; 2017 Nov; 7(1):15441. PubMed ID: 29133857
[TBL] [Abstract][Full Text] [Related]
6. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.
Hou X; Zhou C; Liang Z; Qiu H; Zhou Z; Zheng H; Li Z; Wang Y; Qi X; Lu L; Cao Y; Zheng J
Phytomedicine; 2023 Dec; 121():155093. PubMed ID: 37783131
[TBL] [Abstract][Full Text] [Related]
7. K-ras 4A and 4B mRNA levels correlate with superoxide in lung adenocarcinoma cells, while at the protein level, only mutant K-ras 4A protein correlates with superoxide.
Calvert RJ; Gupta M; Maciag A; Shiao YH; Anderson LM
Lung Cancer; 2013 Jun; 80(3):263-9. PubMed ID: 23474128
[TBL] [Abstract][Full Text] [Related]
8. KRAS induces lung tumorigenesis through microRNAs modulation.
Shi L; Middleton J; Jeon YJ; Magee P; Veneziano D; Laganà A; Leong HS; Sahoo S; Fassan M; Booton R; Shah R; Crosbie PAJ; Garofalo M
Cell Death Dis; 2018 Feb; 9(2):219. PubMed ID: 29440633
[TBL] [Abstract][Full Text] [Related]
9. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.
Kumar MS; Hancock DC; Molina-Arcas M; Steckel M; East P; Diefenbacher M; Armenteros-Monterroso E; Lassailly F; Matthews N; Nye E; Stamp G; Behrens A; Downward J
Cell; 2012 Apr; 149(3):642-55. PubMed ID: 22541434
[TBL] [Abstract][Full Text] [Related]
10. Methylation Status of miR-34a and miR-126 in Non-Small Cell Lung Cancer (NSCLC) Tumor Tissues.
Mehrzad N; Zamani MS; Rahimi A; Shamaei M; Karimipoor M
Iran Biomed J; 2024 Jan; 28(1):53-8. PubMed ID: 38445462
[TBL] [Abstract][Full Text] [Related]
11. The proto-oncogene KRAS is targeted by miR-200c.
Kopp F; Wagner E; Roidl A
Oncotarget; 2014 Jan; 5(1):185-95. PubMed ID: 24368337
[TBL] [Abstract][Full Text] [Related]
12.
Lee YS; Lee JY; Song SH; Kim DM; Lee JW; Chi XZ; Ito Y; Bae SC
Mol Cells; 2020 Oct; 43(10):889-897. PubMed ID: 33115981
[No Abstract] [Full Text] [Related]
13. A KRAS-responsive long non-coding RNA controls microRNA processing.
Shi L; Magee P; Fassan M; Sahoo S; Leong HS; Lee D; Sellers R; Brullé-Soumaré L; Cairo S; Monteverde T; Volinia S; Smith DD; Di Leva G; Galuppini F; Paliouras AR; Zeng K; O'Keefe R; Garofalo M
Nat Commun; 2021 Apr; 12(1):2038. PubMed ID: 33795683
[TBL] [Abstract][Full Text] [Related]
14. Promoter A1312C mutation leads to microRNA-7 downregulation in human non-small cell lung cancer.
Chen S; Wang H; Guo M; Zhao X; Yang J; Chen L; Zhao J; Chen C; Zhou Y; Xu L
Cell Signal; 2024 May; 117():111095. PubMed ID: 38346527
[TBL] [Abstract][Full Text] [Related]
15. Prospects of microRNAs as therapeutic biomarkers in non-small cell lung cancer.
Samson JS; Parvathi VD
Med Oncol; 2023 Nov; 40(12):345. PubMed ID: 37922117
[TBL] [Abstract][Full Text] [Related]
16. Targeting lactate dehydrogenase B-dependent mitochondrial metabolism affects tumor initiating cells and inhibits tumorigenesis of non-small cell lung cancer by inducing mtDNA damage.
Deng H; Gao Y; Trappetti V; Hertig D; Karatkevich D; Losmanova T; Urzi C; Ge H; Geest GA; Bruggmann R; Djonov V; Nuoffer JM; Vermathen P; Zamboni N; Riether C; Ochsenbein A; Peng RW; Kocher GJ; Schmid RA; Dorn P; Marti TM
Cell Mol Life Sci; 2022 Jul; 79(8):445. PubMed ID: 35877003
[TBL] [Abstract][Full Text] [Related]
17. E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer.
Li K; Zheng X; Tang H; Zang YS; Zeng C; Liu X; Shen Y; Pang Y; Wang S; Xie F; Lu X; Luo Y; Li Z; Bi W; Jia X; Huang T; Wei R; Huang K; Chen Z; Zhu Q; He Y; Zhang M; Gu Z; Xiao Y; Zhang X; Fletcher JA; Wang Y
J Exp Med; 2021 Aug; 218(8):. PubMed ID: 34143182
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-mediated reversion of oncogenic KRAS mutation results in increased proliferation and reveals independent roles of Ras and mTORC2 in the migration of A549 lung cancer cells.
Werner AN; Kumar AI; Charest PG
Mol Biol Cell; 2023 Dec; 34(13):ar128. PubMed ID: 37729017
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC.
Joshi P; Jeon YJ; Laganà A; Middleton J; Secchiero P; Garofalo M; Croce CM
Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8650-5. PubMed ID: 26124099
[TBL] [Abstract][Full Text] [Related]
20. Miz1 promotes KRAS-driven lung tumorigenesis by repressing the protocadherin Pcdh10.
Yang J; Hou C; Wang H; Perez EA; Do-Umehara HC; Dong H; Arunagiri V; Tong F; Van Scoyk M; Cho M; Liu X; Ge X; Winn RA; Ridge KM; Wang X; Chandel NS; Liu J
Cancer Lett; 2023 Feb; 555():216025. PubMed ID: 36538983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
